✦ LIBER ✦

Altered therapy schedules in postoperative treatment of patients with malignant gliomas

✍ Scribed by Bogdan Gliński; Paweł Dymek; Jan Skołyszewski

Book ID: 110228961
Publisher: Springer US
Year: 1998
Tongue: English
Weight: 28 KB
Volume: 36
Category: Article
ISSN: 0167-594X
DOI: 10.1023/a:1005760123991

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Postoperative communicating hydrocephalu

Postoperative communicating hydrocephalus in patients with supratentorial malignant glioma

✍ Joji Inamasu; Yoshiki Nakamura; Ryoichi Saito; Yoshiaki Kuroshima; Keita Mayanag 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 351 KB

The results of postoperative irradiation

The results of postoperative irradiation in malignant glioma patients

✍ Agnieszka Florek; Andrzej Wieczorek; Bogumił Selerski; Ryszard Mężyk; Stanisław 📂 Article 📅 2005 🏛 Wielkopolskie Centrum Onkologii 🌐 Polish ⚖ 609 KB

Combined postoperative treatment of mali

Combined postoperative treatment of malignant supratentorial gliomas with vincristine sulphate and radiotherapy

✍ D. Áfra; L. Zoltán; Gy. Gyenes; S. Eckhardt 📂 Article 📅 1973 🏛 Springer Vienna 🌐 English ⚖ 510 KB

Genomic instability and p53 alterations

Genomic instability and p53 alterations in patients with malignant glioma

✍ Vedrana Milinkovic; Jasna Bankovic; Miodrag Rakic; Nebojsa Milosevic; Tijana Sta 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 732 KB

Anti-angiogenic gene therapy in the trea

Anti-angiogenic gene therapy in the treatment of malignant gliomas

✍ NaTosha N. Gatson; E. Antonio Chiocca; Balveen Kaur 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 370 KB

Treatment of malignant gliomas with surg

Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy

✍ Felipe Vega; Luis Davila; Gilles Chatellier; Jacques Chiras; François Fauchon; P 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 373 KB

Fourty patients with malignant supratentorial gliomas received iterative intraarterial (IA) infusions of ACNU, 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea at a dose of 150 mg repeated every 6 weeks. Group A consisted of eighteen patients previously treated with surgery,